The NAD Supplement Story Just Changed (New Evidence)

Summary

NAD is a coenzyme involved in mitochondrial energy production and other cellular processes. Its levels decline with age, prompting interest in supplements that may raise them.

Early research in cells and animals suggested that raising NAD could improve some Parkinson’s-related cellular problems and movement symptoms. Small human studies also found that nicotinamide riboside (NR), an NAD precursor, increased NAD levels and hinted at possible symptom improvement.

A larger, year-long, randomized, double-blind, placebo-controlled trial tested NR in about 400 people with early-stage Parkinson’s disease. Participants took 1 gram per day or a placebo.

NR raised NAD levels in the blood, though its effects in the brain were less clear. Parkinson’s symptoms did not improve; some symptom measures worsened slightly in the NR group. The difference was statistically significant but below the threshold considered clinically important.

These findings do not show that NR causes Parkinson’s disease, nor do they settle whether NR could help in other contexts. The reason for the worsening is uncertain, and more research is needed.

Takeaway: Be cautious about supplement claims. Results from cells, animals, and short preliminary trials do not establish real-world benefits in people. Larger, longer, well-controlled studies are important before drawing conclusions. The video does not advise viewers to start or stop NR.

Presenter and Sources

• Presenter: Dr. Gil Carvalho, Nutrition Made Simple!
• Sources discussed: Laboratory research in cells and animals; two small randomized human studies of about 20 participants each; and a larger, year-long, randomized, double-blind, placebo-controlled trial in about 400 people with early-stage Parkinson’s disease.